Inflammation Corneal

Ophthalmology
1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

O
OculisZUG, Switzerland
1 program
1
OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mLPhase 21 trial
Active Trials
NCT04130802CompletedEst. Jan 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
OculisOCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL

Clinical Trials (1)

NCT04130802OculisOCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL

OCS-01 in Treating Inflammation and Pain in Post-cataract Patients

Start: Sep 2019Est. completion: Jan 2020
Phase 2Completed

Related Jobs in Ophthalmology

Lead Data Manager

Genomics
Remote
11h ago

Cleanroom and Laboratory Technician

SAB BIO
11h ago

Material Handler - 8 Hour Day Shift

Pfizer
United States - Kansas - McPherson
Yesterday

Senior Process Technician - Rotating 2nd Shift

Pfizer
United States - Massachusetts - Andover
Yesterday
$27 - $45/hr

Staff Equipment and Systems Engineer

Johnson & Johnson
Plymouth, Minnesota, United States of America
Yesterday
$94K - $152K/yr

APAC Regulatory Affairs Manager

Johnson & Johnson
Singapore, Singapore
Yesterday

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 companies competing in this space

Related Indications

Myopia(127)Cataract(116)Open-Angle Glaucoma(102)Glaucoma(92)Dry Eye(74)Age-Related Macular Degeneration(73)Dry Eye Disease(43)Neovascular Age-related Macular Degeneration(40)Macular Degeneration(37)Diabetic Retinopathy(25)